Serum protein profiling reveals baseline and pharmacodynamic biomarker signatures associated with clinical outcome in mCRC patients treated with chemotherapy ± cediranib
Aurélien Pommier(Centre National de la Recherche Scientifique), Juliane M. Jürgensmeier(AstraZeneca (United Kingdom)), Paulo M. Hoff(Translational Research in Oncology), Robert A. Shaw(University of Sheffield), Jane Robertson(Cancer Research UK), Shethah Morgan(AstraZeneca (United Kingdom)), Stuart Spencer(AstraZeneca (United Kingdom)), Simon T. Barry(AstraZeneca (Singapore))
Cited by 14
Related Papers
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
|Annals of Oncology|2012|1.5k
Challenges and Key Considerations of the Enhanced Permeability and Retention Effect for Nanomedicine Drug Delivery in Oncology
|Cancer Research|2013|1.5k
Challenges and strategies in anti-cancer nanomedicine development: An industry perspective
|Advanced Drug Delivery Reviews|2016|1.1k
Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial
|The Lancet Oncology|2012|526
Phase I Clinical Study of AZD2171, an Oral Vascular Endothelial Growth Factor Signaling Inhibitor, in Patients With Advanced Solid Tumors
|Journal of Clinical Oncology|2007|303